|
1
|
Boyle EM, Pohlman TH, Cornejo CJ and
Verrier ED: Ischemia-reperfusion injury. Ann Thorac Surg. 64
Suppl:S24–S30. 1997. View Article : Google Scholar
|
|
2
|
Buja LM: Myocardial ischemia and
reperfusion injury. Cardiovasc Pathol. 14:170–175. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jordan JE, Zhao ZQ and Vinten-Johansen J:
The role of neutrophils in myocardial ischemia-reperfusion injury.
Cardiovasc Res. 43:860–878. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Q, Li J, Jubair S, Wang D, Luo Y, Fan
D and Janicki JS: Sparstolonin B attenuates hypoxia-induced
apoptosis, necrosis and inflammation in cultured rat left
ventricular tissue slices. Cardiovasc Drugs Ther. 28:433–439. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hale SL and Kloner RA: Mild hypothermia as
a cardioprotective approach for acute myocardial infarction:
Laboratory to clinical application. J Cardiovasc Pharmacol Ther.
16:131–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Inderberg-Suso EM, Trachsel S, Lislerud K,
Rasmussen AM and Gaudernack G: Widespread CD4+ T-cell
reactivity to novel hTERT epitopes following vaccination of cancer
patients with a single hTERT peptide GV1001. Oncoimmunology.
1:670–686. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stevenson CL: Advances in peptide
pharmaceuticals. Curr Pharm Biotechnol. 10:122–137. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bernhardt SL, Gjertsen MK, Trachsel S,
Møller M, Eriksen JA, Meo M, Buanes T and Gaudernack G: Telomerase
peptide vaccination of patients with non-resectable pancreatic
cancer: A dose escalating phase I/II study. Br J Cancer.
95:1474–1482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brunsvig PF, Aamdal S, Gjertsen MK,
Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S,
Møller M, Eriksen JA and Gaudernack G: Telomerase peptide
vaccination: A phase I/II study in patients with non-small cell
lung cancer. Cancer Immunol Immunother. 55:1553–1564. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brunsvig PF, Kyte JA, Kersten C, Sundstrøm
S, Møller M, Nyakas M, Hansen GL, Gaudernack G and Aamdal S:
Telomerase peptide vaccination in NSCLC: A phase II trial in stage
III patients vaccinated after chemoradiotherapy and an 8-year
update on a phase I/II trial. Clin Cancer Res. 17:6847–6857. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Middleton G, Ghaneh P, Costello E,
Greenhalf W and Neoptolemos JP: New treatment options for advanced
pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2:673–696.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Greten TF, Forner A, Korangy F, N'Kontchou
G, Barget N, Ayuso C, Ormandy LA, Manns MP, Beaugrand M and Bruix
J: A phase II open label trial evaluating safety and efficacy of a
telomerase peptide vaccination in patients with advanced
hepatocellular carcinoma. BMC Cancer. 10:2092010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kyte JA, Gaudernack G, Dueland S, Trachsel
S, Julsrud L and Aamdal S: Telomerase peptide vaccination combined
with temozolomide: A clinical trial in stage IV melanoma patients.
Clin Cancer Res. 17:4568–4580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hunger RE, Lang K Kernland, Markowski CJ,
Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR and
Gaudernack G: Vaccination of patients with cutaneous melanoma with
telomerase-specific peptides. Cancer Immunol Immunother.
60:1553–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kokhaei P, Palma M, Hansson L, Osterborg
A, Mellstedt H and Choudhury A: Telomerase (hTERT 611–626) serves
as a tumor antigen in B-cell chronic lymphocytic leukemia and
generates spontaneously antileukemic, cytotoxic T cells. Exp
Hematol. 35:297–304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi J, Kim H, Kim Y, Jang M, Jeon J,
Hwang YI, Shon WJ, Song YW, Kang JS and Lee WJ: The
anti-inflammatory effect of GV1001 mediated by the downregulation
of ENO1-induced pro-inflammatory cytokine production. Immune Netw.
15:291–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang JE, Kim HJ, Yi E, Jheon S and Kim K:
Reduction of ischaemia-reperfusion injury in a rat lung
transplantation model by low-concentration GV1001. Eur J
Cardiothorac Surg. 50:972–979. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koo TY, Yan JJ and Yang J: Protective
effect of peptide GV1001 against renal ischemia-reperfusion injury
in mice. Transplant Proc. 46:1117–1122. 2014; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yaoita H, Ogawa K, Maehara K and Maruyama
Y: Attenuation of ischemia/reperfusion injury in rats by a caspase
inhibitor. Circulation. 97:276–281. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimamoto A, Chong AJ, Yada M, Shomura S,
Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring
DJ, et al: Inhibition of Toll-like receptor 4 with eritoran
attenuates myocardial ischemia-reperfusion injury. Circulation. 114
1 Suppl:I270–I274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arslan F, Smeets MB, O'Neill LA, Keogh B,
McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA,
Pasterkamp G and de Kleijn DP: Myocardial ischemia/reperfusion
injury is mediated by leukocytic Toll-like receptor-2 and reduced
by systemic administration of a novel anti-Toll-like receptor-2
antibody. Circulation. 121:80–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haskó G, Linden J, Cronstein B and Pacher
P: Adenosine receptors: Therapeutic aspects for inflammatory and
immune diseases. Nat Rev Drug Discov. 7:759–770. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pitarys CJ II, Virmani R, Vildibill HD Jr,
Jackson EK and Forman MB: Reduction of myocardial reperfusion
injury by intravenous adenosine administered during the early
reperfusion period. Circulation. 83:237–247. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Janier MF, Vanoverschelde JL and Bergmann
SR: Adenosine protects ischemic and reperfused myocardium by
receptor-mediated mechanisms. Am J Physiol. 264:H163–H170.
1993.PubMed/NCBI
|
|
25
|
Hausenloy DJ and Yellon DM: Myocardial
ischemia-reperfusion injury: A neglected therapeutic target. J Clin
Invest. 123:92–100. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nian M, Lee P, Khaper N and Liu P:
Inflammatory cytokines and postmyocardial infarction remodeling.
Circ Res. 94:1543–1553. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao Z, Hu Y, Wu W, Ha T, Kelley J, Deng C,
Chen Q, Li C, Li J and Li Y: The TIR/BB-loop mimetic AS-1 protects
the myocardium from ischaemia/reperfusion injury. Cardiovasc Res.
84:442–451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Disis ML: Mechanism of action of
immunotherapy. Semin Oncol. 41 Suppl 5:S3–S13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mazzola P, Radhi S, Mirandola L, Annoni G,
Jenkins M, Cobos E and Chiriva-Internati M: Aging, cancer, and
cancer vaccines. Immun Ageing. 9:42012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martínez P and Blasco MA: Telomeric and
extra-telomeric roles for telomerase and the telomere-binding
proteins. Nat Rev Cancer. 11:161–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choi I, Choi J, Kim J, Oh SY, Kim S and
Lee E: AB0125 the effect of Gv1001, a peptide vaccine, in animal
model of rheumatoid arthritis. Annals Rheumat Dis. 73:8452014.
View Article : Google Scholar
|
